GHRP-2
Growth hormone-releasing peptide-2; Pralmorelin
Source type: Human study. Sources checked .
What the cited research examined
A diagnostic study evaluated GH responses to intravenous GHRP-2 in healthy participants and patients.
Diagnostic test performance does not establish benefits or a routine self-administration schedule.
Reference facts
- Half-life
- Not established for general human use by the cited source.
- Human dose range
- Not provided. This reference does not recommend a human dose.
- Administration interval
- Not established by these sources. A half-life is not a dosing schedule.
- Storage
- Product-specific information required. These sources do not establish a storage specification.
Safety context
FDA notes immune concerns and reported serious adverse events.
Research results and substance listings are not product approvals. The FDA overview distinguishes current Category 2 entries from withdrawn nominations; withdrawal does not establish safety.
Sources and review method
- Intravenous GH diagnostic test study
- Pralmorelin identity reference
- FDA: bulk substances with potential safety risks (includes withdrawn nominations)
These are bounded summaries of the linked sources, not systematic reviews. An unknown field means that these sources do not establish a general-use value. It does not claim that no other literature exists.
The calculator converts values you provide. The planner organizes entries you choose. Neither tool assesses whether a substance or schedule is appropriate.